<\/p>\n
Pramirol<\/strong> je peror\u00e1ln\u00ed pramipexole<\/strong> (1 mg or 1.5 mg) tablet \u2014 a non-ergot dopamine agonist<\/strong> pou\u017e\u00edvan\u00e1 k l\u00e9\u010db\u011b Parkinson disease<\/strong> a moderate-to-severe restless legs syndrome (RLS)<\/strong>. It directly stimulates dopamine D2\/D3 receptors in the brain, partially substituting for the dopamine that is no longer being made. Pramipexole is excreted almost entirely unchanged by the kidneys — renal dosing is essential. It has the highest D3:D2 selectivity of all clinical dopamine agonists, which may explain its anti-depressant effect (FDA-recognised for depressive symptoms in Parkinson disease). Critical safety signals:<\/strong> poruch impulzivn\u00ed kontroly<\/em> (gambling, hypersexuality, binge eating, compulsive shopping), sudden-onset sleep<\/em> (sleep attacks while driving), and orthostatic hypotension. Dose must be titrated up slowly and tapered down slowly — never stopped abruptly.<\/p>\n<\/div>\n \ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n Na\u0161e generick\u00e9 l\u00e9ky poch\u00e1zej\u00ed od v\u00fdrobc\u016f certifikovan\u00fdch WHO-GMP a jsou expedov\u00e1ny po cel\u00e9m sv\u011bt\u011b v diskr\u00e9tn\u00edm, nen\u00e1padn\u00e9m balen\u00ed \u2013 na vn\u011bj\u0161\u00ed stran\u011b bal\u00edku nen\u00ed uveden n\u00e1zev l\u00e9ku. Platby kartou jsou sm\u011brov\u00e1ny prost\u0159ednictv\u00edm regulovan\u00e9ho procesoru (popisky na v\u00fdpisu zahrnuj\u00ed regulovan\u00e9ho procesora plateb kartou \u2013 nikdy \u201cMedsBase\u201d nebo n\u00e1zev l\u00e9ku). P\u0159ij\u00edm\u00e1me tak\u00e9 kryptom\u011bny a bankovn\u00ed p\u0159evody SEPA. Ka\u017ed\u00e1 objedn\u00e1vka je zaji\u0161t\u011bna na\u0161\u00ed politikou p\u0159eposl\u00e1n\u00ed.<\/p>\n Pramirol is an oral tablet containing pramipexole 1 mg or 1.5 mg<\/strong>. pramipexole is a non-ergot dopamine D2\/D3 receptor agonist<\/strong>, originally introduced as Mirapex \/ Mirapexin \/ Sifrol<\/strong>. Pramirol is manufactured by a WHO-GMP certified facility and is bioequivalent to the originator brand at the same strength.<\/p>\n Pramipexole is one of the two most widely used non-ergot dopamine agonists (the other is ropinirole). It is suitable as monotherapy in early Parkinson disease — particularly in younger patients where delaying levodopa is desirable — and as adjunct in advanced disease. Distinctively among Parkinson medications, pramipexole has documented anti-depressant activity and is sometimes specifically chosen in PD patients who have prominent depressive symptoms. It is also licensed for moderate-to-severe restless legs syndrome.<\/p>\n Pramipexole directly stimulates dopamine D2 and D3 receptors, with markedly higher affinity for D3 than D2 — the highest D3 selectivity of any clinically used dopamine agonist. D3 receptors are concentrated in the limbic system, which may explain the documented anti-depressant effect seen with pramipexole that is less prominent with other agonists. It does not affect serotonin 5-HT2B receptors, so does not cause cardiac valve fibrosis. Excretion is almost entirely renal — the kidney handles >90% unchanged.<\/p>\n Pramirol is appropriate for adults with Parkinson disease (monotherapy in early disease, adjunct to levodopa in advanced disease) and for moderate-to-severe restless legs syndrome unresponsive to non-pharmacological measures and iron repletion. It is sometimes specifically chosen in Parkinson patients with prominent depressive symptoms because of its independent anti-depressant action. Younger PD patients (under 65) often benefit from starting with a dopamine agonist before levodopa, to delay levodopa-induced dyskinesia.<\/p>\n Dopamine agonist therapy must<\/strong> be titrated upwards over weeks to avoid intolerable nausea, postural hypotension and somnolence. The dose schedule below is a typical starting framework — your neurologist will tailor it to your response.<\/p>\nPro\u010d objedn\u00e1vat z MedsBase<\/h3>\n
What Is Pramirol?<\/h2>\n
How Does Pramirol (pramipexole) Work?<\/h2>\n
Who Is Pramirol For?<\/h2>\n
Dosing and Titration<\/h2>\n